Alpha RegistryClaim a profile
Published mark

RECURSION PHARMACEUTICALS, INC.

NASDAQ: RXRX. Canonical company identity and public leadership record.

US

Record source reportedRecord not claimedNo Eval published
Follow companySave PDF
Alpha ID
alpha:company:deb8693a-bb09-4c17-bce8-ce6df4ea2ed1
SEC CIK
0001601830
Record version
vpublic-1:ro-d751713988987e9331980363e24189ce, published Oct 26, 2026
Newest evidence
Apr 30, 2026
Monitoring
Not yet monitored Details
Integrity
Not yet signed Methodology
CEO
Nazar KhanSince Apr 30, 2026
Chair
Not published
Independent
Not published10 directors published
Published claims
252 distinct sources
Evidence records
50 pinned
Source conflicts
0None open

Built from 2 distinct sources and 5 evidence records. Every Claim links to where it appears. Where nothing was published, the record states the coverage gap.

CorroboratedSource reportedAlpha inferenceNot disclosed

Public record. Alpha publishes governance facts about this organization from regulatory filings and company statements. Private enterprise overlay data is never projected here. The company can claim the record, correct, or dispute any Claim. How this works

EXECUTIVE APPOINTED

David Hallett executive of RECURSION PHARMACEUTICALS, INC., effective 2026-04-30.

EffectiveEffective Apr 30, 2026E4

Monitoring

Continuous

What the published record states about identity, evidence, evaluation, monitoring, authority, and freshness. Watched-source schedules are not published for this record.

  • Identityunclaimed
    Published
  • Evidencesource_reported
    Published
  • Evaluationnot_evaluated
    Published
  • MonitoringNot yet published for this record.
    Not published
  • AuthorityNot yet published for this record.
    Not published
  • Freshnesscurrent
    Published

Leadership

Evidence
RolePersonSinceStatusClaim
Chief Scientific OfficerDavid HallettApr 2026currentSource reportedE4
Chief Executive Officer and PresidentNazar KhanApr 2026currentSource reportedE5
Chief Financial Officer and President of Recursion UKBen TaylorNot capturedunknownSource reportedE3
Chief Executive Officer and PresidentNajat Khan, Ph.D.Not capturedunknownSource reportedE3

Board of directors

Evidence

10 directors published. Independence determinations are not published for every director.

DirectorStatusSinceCommitteesClaim
Blake BorgesonIndependence not published2013None publishedSource reportedE2
Christopher GibsonIndependence not published2013None publishedSource reportedE2
Dean Y. LiIndependence not published2013None publishedSource reportedE2
Elaine SunIndependence not published2025None publishedSource reportedE2
Franziska MichorIndependence not published2024None publishedSource reportedE2
Najat KhanIndependence not published2024None publishedSource reportedE2
Namandjé BumpusIndependence not published2025None publishedSource reportedE2
Robert HershbergIndependence not published2020None publishedSource reportedE2
Zachary BogueIndependence not published2018None publishedSource reportedE2
Zavain DarIndependence not published2016None publishedSource reportedE2
Blake Borgeson, Ph.D.IndependentNot publishedNone publishedSource reportedE3
Dean Y. Li, M.D., Ph.D.IndependentNot publishedNone publishedSource reportedE3
Franziska Michor, Ph.D.IndependentNot publishedNone publishedSource reportedE3
Najat Khan, Ph.D.Not independentNot publishedPresident and DirectorSource reportedE3
Namandjé Bumpus, Ph.D.IndependentNot publishedNone publishedSource reportedE3
Robert Hershberg, M.D., Ph.D.IndependentNot publishedNone publishedSource reportedE3
Zachary Bogue, J.D.IndependentNot publishedNone publishedSource reportedE3

Committees and risk ownership

Evidence
CommitteeChairMembersRisks assigned
President and DirectorNot publishedNajat Khan, Ph.D.Not described in the published record

Control and voting power

Evidence

No published claims

Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.

Authority to act

Evidence and agent registry

Who can act for the company, and on whose authority. This is what a counterparty's agent checks before it accepts an order, signs, or pays.

Principal executive officerNazar Khan, Chief Executive Officer and President, from Apr 30, 2026
Source reportedE5
company:deb8693a-bb09-4c17-bce8-ce6df4ea2ed1:leadership_role:25
Who can authorize an agentNot assessedNo Alpha inference about signing authority or board-reserved matters is published for this record.
Not assessed
bind
AI agents registered by the companyNot registered in the public RegistryAgent Deployments, Agent Use Cases, Authority Grants, TrustChecks, Action Ledger entries and Governance Receipts live in the private enterprise overlay. They are never projected into the public Registry without explicit cross-plane authorization. Absence here is a plane boundary, not evidence that the enterprise operates no agents.
Agent registry
agents
Delegations publishedNot disclosedBoard and officer delegation resolutions are not public filings and are not published in this record.
Search scope
delegations

Financials and market context

Evidence
Security ListingRXRX (NASDAQ)
Source reportedE1
company:deb8693a-bb09-4c17-bce8-ce6df4ea2ed1:security_listing:26
Index membershipsNo current membership is published in Alpha's tracked index universe.This is not evidence that the company is absent from every market index.
None publishedAs of Oct 26, 2026. Rights-filtered public evidence only; no redistribution or model training is granted. Only source-backed memberships with an explicit public redistribution basis are returned.

Governance and policies

Evidence

No published claims

Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.

Risk, audit, and cyber

Evidence

No published claims

Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.

AI oversight and accountability

Evidence

No published claims

Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.

Compensation

Evidence

No published claims

Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.

Other published claims

Evidence

Published Claims that belong to no section above. Each keeps its permalink, evidence, and assertion state.

Legal NameRECURSION PHARMACEUTICALS, INC.
Source reportedE1
company:deb8693a-bb09-4c17-bce8-ce6df4ea2ed1:legal_name:1
Entity StatusPublic listing published
Source reportedE1
company:deb8693a-bb09-4c17-bce8-ce6df4ea2ed1:entity_status:3

Not yet in this record

Coverage

A gap is a coverage state, not a negative finding. These sections are expected for this entity class and are not yet published.

  • Corporate structureNot reviewed. Parent, subsidiary and predecessor structure explains who is governed.
  • OwnershipNot reviewed. Ownership and voting power determine who can influence the board.
  • FinancialsNot reviewed. Governance-relevant financial context frames capital and audit decisions.
  • CompensationNot reviewed. Pay design shows how incentives are governed.
  • GovernanceNot reviewed. Governing documents and provisions set the rules of the enterprise.
  • Shareholder governanceNot reviewed. Meeting and vote records show shareholder dissent and support.
  • AuditNot reviewed. Auditor, controls and restatements show assurance over reporting.
  • LegalNot reviewed. Material legal and regulatory matters show enforcement exposure.
  • RiskNot reviewed. Risk ownership links the board, committees, executives and controls.
  • CyberNot reviewed. Cyber and data governance is a disclosed oversight domain.
  • AI governanceNot reviewed. AI oversight is a differentiated Alpha governance domain.
  • Markets externalNot reviewed. Auditors, advisors, investors and regulators form the external ecosystem.
  • Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.
  • Only explicitly published canonical company identity and current confirmed public roles are included.Only explicitly published canonical company identity and current confirmed public roles are included.
  • Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.
  • Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.
  • This Company Profile is an identity and evidence record, not an Alpha rating.This Company Profile is an identity and evidence record, not an Alpha rating.

Subject and corrections

Public-role doctrine

This record exists because the company is in the published Registry. The company can claim the record, correct, or dispute any Claim. Corrections are versioned and the original stays in history.

Basis
Published company record built from public sources
Sources
5 evidence records cited. 0 with redistribution rights.
Never published
Private enterprise overlay data: deployments, authority grants, TrustChecks, receipts, telemetry
Record claimed
No
Open disputes
0
Identity ownership
unclaimed
Claiming not yet available

If the company claims the record, its statements appear as their own assertion state and never overwrite the cited evidence.

Evidence

Authority and rights
  1. E1
    Alpha canonical company public projection
    Alpha canonical company public projection. canonical identity. Retrieved Oct 26, 2026. Cited by 4 Claims.
    Open web
    Rights not recorded, link only
    Evidence not pinned
  2. E2
    DEF 14A rxrx-20260430.htm
    sec proxy. Published Apr 30, 2026. Retrieved Sep 2, 2026. Cited by 10 Claims.
    Authoritative, regulatory filing
    Rights not recorded, link only
    Evidence not pinned
  3. E3
    SEC DEF 14A 0001601830-26-000065
    sec def 14a. Published Apr 30, 2026. Retrieved Sep 12, 2026. Cited by 9 Claims.
    Authoritative, regulatory filing
    Rights not recorded, link only
    Evidence not pinned
  4. E4
    RXRX DEF 14A executive officers
    sec filing. Published Apr 30, 2026. Retrieved May 5, 2026. Cited by 1 Claim.
    Authoritative, regulatory filing
    Rights not recorded, link only
    Evidence not pinned
  5. E5
    RXRX DEF 14A executive officers
    sec filing. Published Apr 30, 2026. Retrieved May 5, 2026. Cited by 1 Claim.
    Authoritative, regulatory filing
    Rights not recorded, link only
    Evidence not pinned

What changed in version public-1:ro-d751713988987e9331980363e24189ce

vpublic-1:ro-d751713988987e9331980363e24189ce published Oct 26, 2026
  • David Hallett executive of RECURSION PHARMACEUTICALS, INC., effective 2026-04-30.
  • Nazar Khan executive of RECURSION PHARMACEUTICALS, INC., effective 2026-04-30.
  • Elaine Sun seat on RECURSION PHARMACEUTICALS, INC., effective 2025-01-01.
  • Namandjé Bumpus seat on RECURSION PHARMACEUTICALS, INC., effective 2025-01-01.
  • Franziska Michor seat on RECURSION PHARMACEUTICALS, INC., effective 2024-01-01.
  • Najat Khan seat on RECURSION PHARMACEUTICALS, INC., effective 2024-01-01.
  • Robert Hershberg seat on RECURSION PHARMACEUTICALS, INC., effective 2020-01-01.
  • Zachary Bogue seat on RECURSION PHARMACEUTICALS, INC., effective 2018-01-01.
  • Zavain Dar seat on RECURSION PHARMACEUTICALS, INC., effective 2016-01-01.
  • Blake Borgeson seat on RECURSION PHARMACEUTICALS, INC., effective 2013-01-01.
  • Christopher Gibson seat on RECURSION PHARMACEUTICALS, INC., effective 2013-01-01.
  • Dean Y. Li seat on RECURSION PHARMACEUTICALS, INC., effective 2013-01-01.
Appearance

Alpha Governance PBC. The Registry records reported facts and Alpha's assessments separately. A missing fact is not evidence that it is false.

Record alpha:company:deb8693a-bb09-4c17-bce8-ce6df4ea2ed1, version public-1:ro-d751713988987e9331980363e24189ce. https://registry.alpha.ac/companies/recursion-pharmaceuticals-inc

Navigate

On this record

  1. Overview
  2. Monitoring4
  3. Leadership4
  4. Board17
  5. Committees1
  6. Control and voting0
  7. Authority to act4
  8. Financials1
  9. Governance0
  10. Risk0
  11. AI oversight0
  12. Legal0
  13. Compensation0
  14. Other published claims3
  15. Coverage gaps17
  16. Linked people20
  17. Subject and corrections6
  18. Evidence5
  19. Version historyvpublic-1:ro-d751713988987e9331980363e24189ce

Linked records

Registry

Appearance

esc
  • Actions
    Switch to agent viewJSON, Markdown, MCP
  • Copy Alpha IDalpha:company:deb8693a-bb09-4c17-bce8-ce6df4ea2ed1
  • Cite this recordRECURSION PHARMACEUTICALS, INC.
  • Copy canonical URLregistry.alpha.ac/companies/recursion-pharmaceuticals-inc
  • Copy as MarkdownWith assertion states
  • Report an error
  • Theme: System
  • Theme: Light
  • Theme: Dark
  • Records
    RECURSION PHARMACEUTICALS, INC.Company
  • David HallettPerson
  • Nazar KhanPerson
  • Ben TaylorPerson
  • Najat Khan, Ph.D.Person
  • Blake BorgesonPerson
  • Christopher GibsonPerson
  • Dean Y. LiPerson
  • Elaine SunPerson
  • Franziska MichorPerson
  • Najat KhanPerson
  • Namandjé BumpusPerson
  • Robert HershbergPerson
  • Zachary BoguePerson
  • Zavain DarPerson
  • Blake Borgeson, Ph.D.Person
  • Dean Y. Li, M.D., Ph.D.Person
  • Franziska Michor, Ph.D.Person
  • Namandjé Bumpus, Ph.D.Person
  • Robert Hershberg, M.D., Ph.D.Person
  • Zachary Bogue, J.D.Person
  • Sections
    OverviewRECURSION PHARMACEUTICALS, INC.
  • MonitoringRECURSION PHARMACEUTICALS, INC.
  • LeadershipRECURSION PHARMACEUTICALS, INC.
  • BoardRECURSION PHARMACEUTICALS, INC.
  • CommitteesRECURSION PHARMACEUTICALS, INC.
  • Control and votingRECURSION PHARMACEUTICALS, INC.
  • Authority to actRECURSION PHARMACEUTICALS, INC.
  • FinancialsRECURSION PHARMACEUTICALS, INC.
  • GovernanceRECURSION PHARMACEUTICALS, INC.
  • RiskRECURSION PHARMACEUTICALS, INC.
↑ ↓ move↵ openThis record only

Report an error

Reports attach to the Claim and go to an Alpha analyst through the correction form. Corrections are versioned, and the original stays in history.